Citadel Advisors
AMRX icon

Citadel Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Citadel Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.18M Sell
577,419
-5,598,318
-91% -$75.2M ﹤0.01% 3770
2025
Q4 		$77.8M Buy
6,175,737
+446,438
+8% +$5.11M 0.01% 1039
2025
Q3 		$57.4M Buy
5,729,299
+104,617
+2% +$939K 0.01% 1255
2025
Q2 		$45.5M Sell
5,624,682
-1,867,347
-25% -$14.1M 0.01% 1306
2025
Q1 		$62.8M Sell
7,492,029
-1,488,939
-17% -$12.4M 0.01% 983
2024
Q4 		$71.1M Buy
8,980,968
+88,675
+1% +$744K 0.01% 981
2024
Q3 		$74M Sell
8,892,293
-1,096,432
-11% -$8.57M 0.01% 920
2024
Q2 		$63.4M Buy
9,988,725
+4,921,242
+97% +$31.2M 0.01% 971
2024
Q1 		$30.7M Sell
5,067,483
-1,429,607
-22% -$8.06M 0.01% 1641
2023
Q4 		$39.4M Buy
6,497,090
+3,808,360
+142% +$17M 0.01% 1364
2023
Q3 		$11.3M Buy
2,688,730
+1,493,222
+125% +$5.57M ﹤0.01% 2528
2023
Q2 		$3.71M Buy
1,195,508
+160,305
+15% +$341K ﹤0.01% 4105
2023
Q1 		$1.44M Buy
1,035,203
+345,449
+50% +$688K ﹤0.01% 5993
2022
Q4 		$1.37M Sell
689,754
-956,839
-58% -$2.14M ﹤0.01% 6213
2022
Q3 		$3.33M Buy
1,646,593
+212,703
+15% +$596K ﹤0.01% 4595
2022
Q2 		$4.56M Sell
1,433,890
-31,230
-2% -$113K ﹤0.01% 3977
2022
Q1 		$6.11M Sell
1,465,120
-130,827
-8% -$579K ﹤0.01% 3796
2021
Q4 		$7.64M Buy
1,595,947
+435,040
+37% +$2.17M ﹤0.01% 3540
2021
Q3 		$6.2M Buy
1,160,907
+534,969
+85% +$2.69M ﹤0.01% 3906
2021
Q2 		$3.21M Buy
625,938
+5,423
+0.9% +$30.8K ﹤0.01% 5438
2021
Q1 		$4.18M Sell
620,515
-859,409
-58% -$4.76M ﹤0.01% 4671
2020
Q4 		$6.76M Buy
1,479,924
+172,597
+13% +$765K ﹤0.01% 3179
2020
Q3 		$5.07M Buy
1,307,327
+717,014
+121% +$3.07M ﹤0.01% 3137
2020
Q2 		$2.81M Buy
590,313
+238,737
+68% +$983K ﹤0.01% 3970
2020
Q1 		$1.22M Sell
351,576
-87,734
-20% -$372K ﹤0.01% 4964
2019
Q4 		$2.12M Sell
439,310
-210,945
-32% -$733K ﹤0.01% 4328
2019
Q3 		$1.89M Buy
650,255
+73,904
+13% +$258K ﹤0.01% 4562
2019
Q2 		$4.13M Buy
+576,351
New +$5.89M ﹤0.01% 3380
2018
Q3 		– Sell
-604,634
Closed -$12.7M – 9163
2018
Q2 		$9.92M Buy
+604,634
New +$10.6M ﹤0.01% 1939

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Citadel Advisors's AMRX Position: Q1 2026 in Review

Citadel Advisors reduced its Amneal Pharmaceuticals (AMRX) stake by 91% in Q1 2026, selling an estimated $75.2M and leaving 577,419 shares worth $7.18M. The position accounts for ﹤0.01% of the portfolio, ranked #3770.

Citadel Advisors first reported a position in AMRX in Q2 2018 and has held it in 29 quarters since. The position peaked at $77.8M in Q4 2025. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Citadel Advisors held 577,419 shares of Amneal Pharmaceuticals worth $7.18M as of Q1 2026.
  • Citadel Advisors sold 5,598,318 Amneal Pharmaceuticals shares in Q1 2026, an estimated $75.2M.
  • Amneal Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3770 holding.
  • Citadel Advisors first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 29 quarters since.
  • Citadel Advisors's Amneal Pharmaceuticals position peaked at $77.8M in Q4 2025.
  • 315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.